Related Experiment Video

Updated: May 19, 2026

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

miRNAs as mediators of drug resistance

Sierk Haenisch1, Ingolf Cascorbi

  • 1Institute of Experimental & Clinical Pharmacology, University Hospital Schleswig-Holstein, Campus Kiel, D-24105 Kiel, Germany.

Epigenomics
|August 28, 2012
PubMed

Insights

Epigenetic modifications, particularly microRNA (miRNA) expression, significantly contribute to tumor chemoresistance. Epigenetic drugs show promise in overcoming chemotherapy nonresponse by targeting these mechanisms.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Tumor chemoresistance is traditionally linked to efflux transporters and genetic pathway alterations.
  • Emerging evidence highlights epigenetic modifications as a key factor in drug resistance.
  • Deregulation of microRNA (miRNA) expression in tumor cells impacts chemotherapy response.

Purpose of the Study:

  • To review major epigenetic mechanisms driving tumor drug resistance.
  • To explore the role of miRNA expression in chemoresistance.
  • To discuss the potential of epigenetic drugs in overcoming chemotherapy nonresponse.

Main Methods:

  • Literature review of epigenetic mechanisms in cancer drug resistance.
  • Analysis of studies on miRNA deregulation and its impact on chemotherapy.
  • Examination of research on epigenetic drugs for overcoming chemoresistance.

Main Results:

  • Epigenetic alterations, including DNA methylation and histone modifications, contribute to chemoresistance.
  • Dysregulated miRNA expression patterns in tumors interfere with drug efficacy.
  • Targeting miRNA expression has shown potential in improving chemotherapy response.
  • Epigenetic drugs offer a strategy to combat chemotherapy nonresponse.

Conclusions:

  • Epigenetic modifications, especially miRNA dysregulation, are critical drivers of tumor chemoresistance.
  • Epigenetic therapies hold significant promise for enhancing conventional chemotherapy efficacy.
  • Further research into epigenetic mechanisms and drug development is crucial for improving cancer treatment outcomes.

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...